<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Apollomics Inc. Class A Ordinary Shares — News on 6ix</title>
<link>https://6ix.com/company/apollomics-inc-class-a-ordinary-shares</link>
<description>Latest news and press releases for Apollomics Inc. Class A Ordinary Shares on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 01 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/apollomics-inc-class-a-ordinary-shares" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835471878dffbe2df0e3424.webp</url>
<title>Apollomics Inc. Class A Ordinary Shares</title>
<link>https://6ix.com/company/apollomics-inc-class-a-ordinary-shares</link>
</image>
<item>
<title>Apollomics Inc. Announces $2.0 Million Bridge Financing</title>
<link>https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-inc-announces-dollar20-million-bridge-financing</link>
<guid isPermaLink="true">https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-inc-announces-dollar20-million-bridge-financing</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>FOSTER CITY, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced that it has entered</description>
</item>
<item>
<title>Apollomics Reports First Half 2025 Financial Results</title>
<link>https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-reports-first-half-2025-210500095</link>
<guid isPermaLink="true">https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-reports-first-half-2025-210500095</guid>
<pubDate>Mon, 22 Dec 2025 21:05:00 GMT</pubDate>
<description>FOSTER CITY, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the first half of 2025 ended June 30, 2025. First Half 2025 Financial Results Ended June 20, 2025 Cash, cash equivalents, bank deposits and money market funds as of June 30, 2025, were $2</description>
</item>
<item>
<title>Apollomics Announces Settlement of Cayman Litigation</title>
<link>https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-announces-settlement-cayman-litigation-223800130</link>
<guid isPermaLink="true">https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-announces-settlement-cayman-litigation-223800130</guid>
<pubDate>Wed, 19 Nov 2025 22:38:00 GMT</pubDate>
<description>FOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM) announced today entering into a settlement agreement (the “Settlement Agreement” or the “Agreement”) with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group Investment Limited (together, “TWVC”), entities represented by Triwise Capital Management Ltd, in connection with the litigation previously filed in the Grand Court of the Cayman Islands (the “Cayman Litigation”</description>
</item>
<item>
<title>Apollomics Announces Changes to its Board of Directors and Composition of Committees</title>
<link>https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-announces-changes-board-directors-040000903</link>
<guid isPermaLink="true">https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-announces-changes-board-directors-040000903</guid>
<pubDate>Tue, 18 Nov 2025 04:00:00 GMT</pubDate>
<description>FOSTER CITY, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California-based late-stage clinical biopharmaceutical company, today announced the following update regarding changes to the Company’s board of directors (“Board”) and composition of committees. On November 16, 2025, Mr. Po-Jen Hsueh resigned from the Board. Mr. Hsueh’s resignation was not related to any disagreement with the Company. Pursuant to a meeting of the Board on Nov</description>
</item>
<item>
<title>Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation</title>
<link>https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-announces-continued-listing-nasdaq-183600554</link>
<guid isPermaLink="true">https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-announces-continued-listing-nasdaq-183600554</guid>
<pubDate>Wed, 15 Oct 2025 18:36:00 GMT</pubDate>
<description>Nasdaq Hearing Cancellation and Continued ListingFOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California based late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, had previously announced that it had filed an application to appeal the delisting notification previously received from the Listing Qualifications Staff (the “</description>
</item>
<item>
<title>Apollomics, Inc. Company Operational Continuity Update</title>
<link>https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-inc-company-operational-continuity-012200759</link>
<guid isPermaLink="true">https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-inc-company-operational-continuity-012200759</guid>
<pubDate>Tue, 14 Oct 2025 01:22:00 GMT</pubDate>
<description>FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced the following company operational update. Apollomics is a clinical-stage biotechnology company advancing innovative oncology therapies to transform the treatment landscape for patients with few or no options. With a pipeline of nine product candidates across 11 programs, including six in clinical development, the Company is focused on tackling some of the most ch</description>
</item>
<item>
<title>Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress</title>
<link>https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-reports-full-2024-financial-200500923</link>
<guid isPermaLink="true">https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-reports-full-2024-financial-200500923</guid>
<pubDate>Thu, 03 Apr 2025 20:05:00 GMT</pubDate>
<description>Strategic collaboration with LaunXP for the development of vebreltinib in combination with an EGFR inhibitor (“EGFRi”) to bring in $10 million upfront payment and expand dataset to combination therapyNew interim data for the vebreltinib development program, including in non-CNS MET fusion tumors and non-small cell lung cancer (NSCLC) with MET amplification$9.8 million in cash and cash equivalents as of December 31, 2024, in conjunction with LaunXP upfront payment, pipeline focus and expense redu</description>
</item>
<item>
<title>Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib</title>
<link>https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-launxp-announce-development-commercialization-120000768</link>
<guid isPermaLink="true">https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-launxp-announce-development-commercialization-120000768</guid>
<pubDate>Mon, 31 Mar 2025 12:00:00 GMT</pubDate>
<description>LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asia (excluding mainland China, Hong Kong and Macau) for the treatment of non-small cell lung cancer (“NSCLC”)Apollomics to receive upfront payments of $10 million, and is eligible for pre-commercial milestones up to $50 million, and royalties on net product sales FOSTER CITY, Calif. and TAIPEI, Taiwan, March 31, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apo</description>
</item>
<item>
<title>Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia</title>
<link>https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-announces-top-line-results-for-phase-3-bridging-trial-of-uproleselan-in-china-in-patients-with-relapsed-or-refractory-acute-myeloid-leukemia</link>
<guid isPermaLink="true">https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-announces-top-line-results-for-phase-3-bridging-trial-of-uproleselan-in-china-in-patients-with-relapsed-or-refractory-acute-myeloid-leukemia</guid>
<pubDate>Fri, 20 Dec 2024 05:00:00 GMT</pubDate>
<description>FOSTER CITY, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical</description>
</item>
<item>
<title>Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split</title>
<link>https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-announces-shareholder-approval-and-effective-date-for-1-for-100-reverse-share-split</link>
<guid isPermaLink="true">https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-announces-shareholder-approval-and-effective-date-for-1-for-100-reverse-share-split</guid>
<pubDate>Thu, 21 Nov 2024 05:00:00 GMT</pubDate>
<description>The Company&apos;s class A ordinary shares will begin trading on a split-adjusted basis on November 25, 2024 FOSTER CITY, Calif., Nov. 21, 2024 (GLOBE</description>
</item>
<item>
<title>Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024</title>
<link>https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-presents-vebreltinib-data-in-patients-with-non-small-cell-lung-cancer-with-metex14-skipping-mutations-at-european-society-for-medical-oncology-esmo-congress-2024</link>
<guid isPermaLink="true">https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-presents-vebreltinib-data-in-patients-with-non-small-cell-lung-cancer-with-metex14-skipping-mutations-at-european-society-for-medical-oncology-esmo-congress-2024</guid>
<pubDate>Mon, 16 Sep 2024 04:00:00 GMT</pubDate>
<description>Vebreltinib is efficacious in both treatment naïve and previously treated patients with NSCLC with METex14 skipping, and regardless of co-occurring MET</description>
</item>
<item>
<title>Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress</title>
<link>https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-reports-first-half-2024-financial-results-and-highlights-vebreltinib-clinical-progress</link>
<guid isPermaLink="true">https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-reports-first-half-2024-financial-results-and-highlights-vebreltinib-clinical-progress</guid>
<pubDate>Wed, 14 Aug 2024 04:00:00 GMT</pubDate>
<description>Continued clinical progress for the vebreltinib registration-enabling program, including new data in non-CNS MET fusion tumors and non-small cell lung cancer</description>
</item>
<item>
<title>Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial</title>
<link>https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-announces-positive-preliminary-data-of-vebreltinib-in-patients-with-non-cns-met-fusion-solid-tumors-from-its-phase-2-sparta-trial</link>
<guid isPermaLink="true">https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-announces-positive-preliminary-data-of-vebreltinib-in-patients-with-non-cns-met-fusion-solid-tumors-from-its-phase-2-sparta-trial</guid>
<pubDate>Tue, 13 Aug 2024 04:00:00 GMT</pubDate>
<description>43% overall response rate: Six confirmed responses (including one complete response in metastatic non-small cell lung cancer and five partial responses)</description>
</item>
<item>
<title>Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement</title>
<link>https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-granted-180-day-extension-to-regain-compliance-with-nasdaq-minimum-bid-price-requirement</link>
<guid isPermaLink="true">https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-granted-180-day-extension-to-regain-compliance-with-nasdaq-minimum-bid-price-requirement</guid>
<pubDate>Tue, 16 Jul 2024 04:00:00 GMT</pubDate>
<description>FOSTER CITY, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical</description>
</item>
<item>
<title>Apollomics Announces Updated Strategic Focus and Leadership Team Changes</title>
<link>https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-announces-updated-strategic-focus-and-leadership-team-changes</link>
<guid isPermaLink="true">https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-announces-updated-strategic-focus-and-leadership-team-changes</guid>
<pubDate>Wed, 03 Jul 2024 04:00:00 GMT</pubDate>
<description>Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical need</description>
</item>
<item>
<title>Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting</title>
<link>https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-announces-vebreltinib-data-at-the-2024-american-society-of-clinical-oncology-asco-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-announces-vebreltinib-data-at-the-2024-american-society-of-clinical-oncology-asco-annual-meeting</guid>
<pubDate>Tue, 04 Jun 2024 04:00:00 GMT</pubDate>
<description>Data from Phase 2 and 2/3 trials demonstrate continued efficacy and safety of vebreltinib for treating different tumor types carrying MET-driver alterations</description>
</item>
<item>
<title>Apollomics Announces Presentation at the 2024 BIO International Convention</title>
<link>https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-announces-presentation-at-the-2024-bio-international-convention</link>
<guid isPermaLink="true">https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-announces-presentation-at-the-2024-bio-international-convention</guid>
<pubDate>Wed, 29 May 2024 04:00:00 GMT</pubDate>
<description>FOSTER CITY, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM), a clinical-stage biopharmaceutical</description>
</item>
<item>
<title>Apollomics Announces Private Placement Financing and Addition to Board of Directors</title>
<link>https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-announces-private-placement-financing-and-addition-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-announces-private-placement-financing-and-addition-to-board-of-directors</guid>
<pubDate>Wed, 08 May 2024 04:00:00 GMT</pubDate>
<description>FOSTER CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a clinical-stage biopharmaceutical company developing multiple oncology</description>
</item>
<item>
<title>Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene</title>
<link>https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-announces-approval-of-vebreltinib-in-china-as-a-first-in-class-treatment-for-gliomas-with-met-fusion-gene</link>
<guid isPermaLink="true">https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-announces-approval-of-vebreltinib-in-china-as-a-first-in-class-treatment-for-gliomas-with-met-fusion-gene</guid>
<pubDate>Thu, 25 Apr 2024 04:00:00 GMT</pubDate>
<description>Apollomics’ partner in China, Avistone, received approval from National Medical Products Administration of China to expand the use of vebreltinib to the</description>
</item>
<item>
<title>Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting</title>
<link>https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-announces-poster-presentations-of-vebreltinib-data-at-the-2024-american-association-for-cancer-research-aacr-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/apollomics-inc-class-a-ordinary-shares/news/apollomics-announces-poster-presentations-of-vebreltinib-data-at-the-2024-american-association-for-cancer-research-aacr-annual-meeting</guid>
<pubDate>Tue, 02 Apr 2024 04:00:00 GMT</pubDate>
<description>FOSTER CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company</description>
</item>
</channel>
</rss>